10results about How to "Reduce compliance" patented technology

The invention provides an alternating field treatment device, equipment and system, a method for controlling electric signal output and electronic equipment. The alternating field treatment device comprises a signal generator which is used for generating one or more electric signals so as to generate an alternating electric field for treating a target area; the amplitude output of the electric signal comprises a rising stage which rises according to a first predefined rule and a falling stage which falls according to a second predefined rule after the rising stage, and in the rising stage, the rising rate of the amplitude of the electric signal is reduced along with the increase of the amplitude. The alternating field equipment, the alternating field system, the method for controlling the output of the electric signal and the electronic equipment are all associated with the alternating field device. Through the arrangement, a patient can tolerate higher treatment power, so that the treatment effect and the patient compliance are improved.

The invention provides a vitamin B6 injection and a preparation method thereof. The vitamin B6 injection is prepared from the following raw materials in parts by weight: 10 to 15 parts of vitamin B6 nanocrystals, 0.5 to 0.8 part of water-soluble fullerene, 1 to 2 parts of tetrahydromethylpyrimidine carboxylic acid, 0.8 to 1 part of a polyglutamic acid-polyethylene glycol compound, 1 to 3 parts of a pH (Potential of Hydrogen) regulator and 100 to 200 parts of water for injection. The vitamin B6 injection provided by the invention has high stability, and the storage time is prolonged to 48 months from the traditional 12 months. Most importantly, a part of the vitamin B6 nanocrystals are loaded on the water-soluble fullerene, a part of the vitamin B6 nanocrystals are coated on the polyglutamic acid-polyethylene glycol compound, and the components are separately prepared and then mixed, so that the prepared vitamin B6 injection is difficult to decompose under illumination and resistant to high temperature, and after an accelerated experiment process, the clarity, pH, content and impurities of the vitamin B6 injection are stable; no obvious change exists, and the application prospect is wide.

The invention discloses a posture and gait training auxiliary device and method suitable for vestibular neuritis patients in the technical field of medical instruments, the posture and gait training auxiliary device comprises guardrails, ground mats and eyeshades, the guardrails are arranged in two groups, and the ground mats are arranged in two groups. During treatment, the patient wears an eyeshade, walks according to a second foot type shown on a second ground mat and requires the patient to walk close to the front foot and the heel, when the feet of the patient are located at the position of the intelligent monitoring assembly on the second foot type, the induction lamp is turned on, the intelligent monitoring assembly starts to work, the intelligent monitoring assembly can adjust the timing range for 2-10 seconds, and the patient can walk on the second foot type. After the body of the patient is stabilized at the body position, the body does not shake or does not shake obviously, the patient walks next step. After the patient finishes four-stage training, the posture gait problem caused by chronic dizziness of the patient can be well improved. The method is low in cost per time, and a treatment place does not need to be in a hospital; the cost for self-rehabilitation treatment of a patient is low, the compliance is good, and the rehabilitation treatment effect can be well achieved.

This invention relates to the field of digital twin technology, and more particularly to a legal compliance full lifecycle management platform based on digital twins. By setting up a model building module, a unit invocation module, a behavior analysis module, an anomaly adjustment module, and a compliance verification module, a digital twin model is constructed and adjusted. Several behavioral data points are input into the model, and the behavioral data is analyzed to run the execution unit. The accuracy of the model's operation is judged based on the execution results. The anomaly adjustment module is invoked to determine the adjustment method based on abnormal operating states, and the adjusted model is subjected to compliance verification to determine its usability. The adjusted model is then put into use. This invention, by constructing a general digital twin model, performing targeted analysis and adjustment of single and complex behaviors, and determining the usability and specificity of the model, improves the accuracy of judgment and analysis efficiency of complex behaviors.

The invention relates to a compound medicine composition and application thereof in resisting helicobacter pylori infection, in particular to the compound medicine composition, a medicine preparation, a preparation method and application, and the composition comprises at least two selected from the following components: (I) Vonoprazan or pharmaceutically acceptable salt thereof, (II) Vonoprazan or pharmaceutically acceptable salt thereof, (III) Vonoprazan or pharmaceutically acceptable salt thereof, (III) Vonoprazan or pharmaceutically acceptable salt thereof, (III) Vonoprazan or pharmaceutically acceptable salt thereof and (III) Vonoprazan or pharmaceutically acceptable salt thereof; (II) amoxicillin or a pharmaceutically acceptable salt thereof; (III) clarithromycin; according to the composition prepared by compounding different anti-infection active ingredients, the problems of patient compliance and medication convenience can be effectively solved, for example, the tablet dosage is reduced, wrong taking, missing taking, excessive taking and the like of a patient are avoided, the stability and safety of the preparation can be accidentally improved, and the content of harmful impurities is particularly reduced.

The invention discloses a natural person identity encryption real-name authentication method and system, and relates to the field of identity and data security. The method is based on a'natural person-encryption terminal-authentication server 'closed-loop encryption architecture, an identity identifier capable of directly recognizing a natural person is not collected, and the core comprises five steps of information collection, authentication initiation, identity authentication, dynamic identity password generation, closed-loop verification and result synchronization. The system adopts a three-level distributed architecture and is composed of an encryption terminal and an authentication server, and the encryption terminal and the authentication server cooperate to achieve secret key fragmentation management, encryption communication and auditing tracing. According to the method, the principle of minimum necessary collection is followed, the national secret algorithm, secret key fragment storage and block chain evidence storage technology are combined, identity authentication is unforgeable, uncounterfeitable and traceable, sensitive information leakage is eradicated from the source, compliance cost is reduced, the method is adaptive to multi-field and multi-terminal scenes, related laws and regulations are met, and high safety and practicability are achieved.

This application discloses a soluble microneedle composition of a GLP-1R agonist and its preparation method, belonging to the field of biomedical technology. It includes a needle body material and a base material. The needle body material contains a small molecule GLP-1R agonist, a penetration enhancer, and a soluble polymeric backbone material, and may further include pH adjusters, humectants, and stabilizers. The base material is composed of polylactic acid, polylactic acid-glycolic acid copolymer, cross-linked polyhyaluronic acid, cross-linked gelatin, polyvinyl alcohol, polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate copolymer, N-(2-hydroxypropyl)methacrylamide polymer, or combinations thereof. Through injection, centrifugation, and drying, an integrated microneedle structure with mechanical strength and rapid dissolution is formed. It can pierce the stratum corneum of the skin to form microchannels and rapidly dissolve and release oxaliplatin subcutaneously, achieving transdermal delivery, effectively reducing gastrointestinal exposure and first-pass metabolism, and improving drug utilization and medication adherence.

The present invention relates to the field of biomedicine, and specifically provides a lyophilized powder and nasal preparation containing neurotoxin, comprising neurotoxin, stabilizer and excipient; the excipient comprises one or more of acidic gelatin, alkaline gelatin and sucrose, and the stabilizer comprises one or more of block polyether F-68, block polyether F-127 and Tween 80; by using the stabilizer comprising one or more of block polyether F-68, block polyether F-127 and Tween 80 and the excipient comprising one or more of acidic gelatin, alkaline gelatin and sucrose, a synergistic effect is produced, so that the stability of the neurotoxin at room temperature is significantly improved, the degradation of the neurotoxin is slowed down, and the time for maintaining the biological activity of the neurotoxin at more than 95% is significantly prolonged, and at the same time, the preparation can be administered nasally, which increases the penetration of the neurotoxin through the blood-brain barrier and greatly reduces the toxicity.

The invention relates to the technical field of pharmaceutical preparations, in particular to a vildagliptin double-release preparation and a preparation method thereof. The invention aims to provide a double-release preparation which has two curative effects of taking effect quickly and persistently on diabetics. The vildagliptin double-release preparation comprises a drug-containing quick-release part and a drug-containing slow-release part, the drug-containing quick-release part comprises a first vildagliptin active component and a slow-release auxiliary material, and the weight of the first vildagliptin active component is 1-20% of the total weight of the drug-containing quick-release part; the drug-containing sustained-release part comprises a second vildagliptin active component and a sustained-release auxiliary material, and the weight of the second vildagliptin active component is 1-15% of the total weight of the drug-containing sustained-release part; the weight ratio of the first vildagliptin active component to the second vildagliptin active component is 1: (1-15). The invention further provides a method for preparing the vildagliptin double-release preparation.

The present invention relates to a composition for preventing or treating diabetes mellitus comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes mellitus. More specifically, the combined administration of a long-acting analogue conjugate and a long-acting insulinotropic peptide conjugate inhibits weight gain due to the administration of insulin and vomiting and nausea due to the administration of insulinotropic peptide, and also reduces the required dose of insulin, thereby significantly enhancing drug compliance. The invention also relates to the administration of a pharmaceutical composition comprising a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide analogue conjugate for reducing the side effects of pancreatic beta cells in a diabetic patient, and to a method for reducing the side effects of pancreatic beta cells in a diabetic patient, comprising the step of administering the composition. Specifically, the present invention is characterized by reducing side effects such as pancreatic beta cell dysfunction, pancreatic beta cell amount reduction, lipotoxicity, or glucotoxicity associated with the progression of diabetes mellitus.